Modified Capecitabine and Oxaliplatin (mCAPOX) for Patients With GI Malignancies

This study is a single arm, non-randomized feasibility study with tolerability and toxicity evaluation as primary endpoints which seeks to determine if a modified administration schedule of capecitabine with oxaliplatin will result in less toxicity than standard FOLFOX or CAPOX regimens.

NCT Number	NCT06648785
Lead Sponsor	University of Vermont Medical Center
Conditions	GI Cancers
Enrollment	20 participants
Start Date	2024-10-21
Primary Completion	2026-11 (estimated)
Study Completion	2026-11 (estimated)
Updated on ClinicalTrials.gov	2026-02-05